Placental epigenetic age and adolescent blood pressure: the Extremely Low Gestational Age Newborn cohort

Anisha Gerber1, Kyle R Roell2, Katelyn K Huff3

  • 1Division of Pediatric Nephrology, Department of Pediatrics, University of Virginia, Charlottesville, VA, USA. anisha.gerber@uvahealth.org.

Pediatric Research
|May 7, 2025
PubMed

Insights

Placental epigenetic age acceleration is linked to higher systolic blood pressure in adolescent males born extremely preterm. This finding suggests placental epigenetic age may serve as a biomarker for cardiovascular risk in this population.

Area of Science:

  • Perinatal epigenetics
  • Developmental origins of health and disease
  • Pediatric cardiovascular health

Background:

  • Extremely preterm birth (<28 weeks' gestation) poses long-term health risks.
  • Placental epigenetic gestational age (eGA) may reflect developmental trajectories.
  • The association between placental eGA acceleration and adolescent cardiovascular health is underexplored.

Purpose of the Study:

  • To investigate the relationship between placental eGA acceleration and adolescent systolic blood pressure (SBP).
  • To explore potential sex differences in this association among individuals born extremely preterm.

Main Methods:

  • Analysis of a subset from the Extremely Low Gestational Age Newborn cohort.
  • Calculation of placental eGA acceleration using the Robust Placental Clock.
  • Mixed effects models to assess the association between eGA acceleration and adolescent SBP, including sex interaction.

Main Results:

  • No significant association was found between placental eGA acceleration and adolescent SBP in the overall cohort (N=193).
  • A significant association was observed in males: each 1-week eGA acceleration correlated with a 3.6 mmHg increase in SBP (p=0.01).
  • No such association was found in females.

Conclusions:

  • Placental eGA acceleration is associated with increased SBP in adolescent males born extremely preterm, but not females.
  • These sex-specific findings support placental eGA as a potential biomarker for childhood cardiovascular outcomes.
  • Further evaluation in diverse cohorts is warranted to validate placental eGA for risk stratification of elevated blood pressure.
Abstract